Education
About Us
Working with TipRanks
Follow Us
MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
MBX Stock Chart & Stats
$31.31
-$0.30(-2.05%)
At close: 4:00 PM EST
$31.31
-$0.30(-2.05%)
Day’s Range― - ―
52-Week Range$4.81 - $44.89
Previous CloseN/A
Volume52.29K
Average Volume (3M)618.85K
Market Cap
$1.41B
Enterprise Value$833.50M
Total Cash (Recent Filing)$391.67M
Total Debt (Recent Filing)$623.00K
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Mar 23, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding44,902,300
10 Day Avg. Volume590,076
30 Day Avg. Volume618,854
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.39
Price to Sales (P/S)0.00
P/FCF Ratio-11.08
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.33K
Enterprise Value/Ebitda-9.44
Forecast
1Y Price Target
$64.20Price Target Upside105.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressA positive Phase 2 readout and a planned Phase 3 materially de-risk the lead program and create a clear path toward registration and commercialization. Simultaneous advancement of multiple metabolic candidates diversifies program risk and supports sustained R&D value creation over the next 2–4 years.
Multi-year Cash RunwayA reported cash balance sufficient to fund operations into 2029 gives management flexibility to execute clinical milestones without immediate financing. This multi-year runway reduces near-term dilution risk, supports sequential Phase 3 starts and additional candidate nominations, and improves partnerability.
Low Leverage And Strengthened Equity BaseExtremely low leverage and a larger equity cushion lower financial distress risk and provide capacity to support ongoing clinical investments. Strong liquidity and minimal debt improve strategic optionality for partnerships or acquisitions while clinical programs mature.
Bears Say
Pre-revenue StatusBeing pre-revenue means value depends entirely on future clinical and commercial success. Without product sales, the company relies on financing or partnerships to sustain operations, amplifying binary program risk and delaying any durable path to positive operating cash flow or earnings.
Widening Net LossesRapidly increasing net losses reflect accelerating operational spend to advance multiple programs. Persistent widening losses without revenue progress can force more dilutive financing, constrain investment choices, and indicate the company has yet to achieve operating leverage from its development activities.
Accelerating Cash BurnSubstantial negative operating cash flow and free cash outflows mean the business is consuming capital quickly to fund trials. Even with current runway, sustained high burn increases the likelihood of future fundraising, potential dilution, and reduced flexibility if clinical timelines slip or additional programs are added.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $44.89 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $1.41B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is Mar 23, 2026 which is in 17 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.062.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.63.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 44,902,300 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 9.712%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.20 (105.05% Upside)
$64.20 (105.05% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 624.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.42%
12-Months-Change
Fundamentals
Return on Equity
-24.43%
Trailing 12-Months
Asset Growth
41.67%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$64.20
▲(105.05% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
Currently, No data available
---